AnteoBind order received and Life Sciences Update
Filed with ASX · · 4 pages · English
BRISBANE, AUSTRALIA, 29 December 2025: AnteoTech Ltd (ASX: ADO) (‘AnteoTech’ or ‘the Company’) is pleased to provide the following update on progress within its Life Sciences business. Key points: • Received a US$185,000 (~AU$275,750)1 order for AnteoBindTM from the Serum Institute of India (SII), with despatch to take place on 5th January 2026, on office re-opening. • SII has agreed to evaluate a
Earlier from AnteoTech
- Ultranode X achieves more than 1,000 Cycles at 80% Capacity
- Joint Development and Sales Agreement Executed
- Full Year Results and Business Update Presentation
- FY2025 Full Year Appendix 4E and Annual Report
- Appointment of MD & CEO and Annual Staff Review Process
Later from AnteoTech
- Trading Halt
- AnteoTech $3.5m Capital Raising
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Yearly Report and Accounts
- Ultranode 95 validated in cell format suited for drone use
Follow AnteoTech into a list and get an email when it puts out news.
Follow AnteoTech